Live price temporarily unavailable.
Ascendis Pharma A/S (ASND) is a Health Care company in the Russell 1000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | €4.61M | €1.53M | €10.6M | €13.4M | €6.95M | €7.78M | €51.2M | €266.7M | €363.6M | €720.1M |
| Growth (year over year) | −43.3% | −66.8% | +591.6% | +26.4% | −48.0% | +11.9% | +557.9% | +421.2% | +36.3% | +98.0% |
| Gross profit | — | — | — | €13.4M | €6.95M | €4.25M | €39.0M | €222.3M | €319.4M | €625.2M |
| Gross margin | — | — | — | 100.0% | 100.0% | 54.7% | 76.3% | 83.4% | 87.8% | 86.8% |
| Operating income | −€72.9M | −€111.5M | −€154.8M | −€226.7M | −€330.6M | −€451.8M | −€561.8M | −€455.5M | −€278.8M | −€136.3M |
| Operating margin | −1583.2% | −7290.3% | −1462.6% | −1695.1% | −4755.1% | −5808.6% | −1097.9% | −170.8% | −76.7% | −18.9% |
| Net income | −€68.5M | −€123.9M | −€130.1M | −€218.0M | −€419.0M | −€383.6M | −€583.2M | −€481.4M | −€378.1M | −€228.0M |
| Net margin | −1487.3% | −8097.8% | −1229.5% | −1630.0% | −6025.5% | −4931.6% | −1139.6% | −180.5% | −104.0% | −31.7% |
| EPS (diluted) | −€2.58 | −€3.68 | −€3.17 | −€4.69 | −€8.28 | −€7.00 | −€10.40 | −€8.55 | −€6.53 | −€3.76 |
| Balance sheet | ||||||||||
| Cash and equivalents | €180.3M | €195.4M | €277.9M | €598.1M | €584.5M | €446.3M | €444.8M | €392.2M | €559.5M | €616.0M |
| Total assets | €190.1M | €211.0M | €319.0M | €676.7M | €979.8M | €1.08B | €1.09B | €825.6M | €1.18B | €1.30B |
| Total liabilities | €13.5M | €23.8M | €38.9M | €79.6M | €141.1M | €201.3M | €826.4M | €971.3M | €1.29B | €1.47B |
| Shareholders' equity | €176.6M | €187.2M | €280.1M | €597.1M | €838.7M | €883.6M | €263.3M | −€145.7M | −€105.7M | −€162.8M |
| Cash flow | ||||||||||
| Operating cash flow | −€60.2M | −€95.1M | −€138.8M | −€175.9M | −€271.5M | −€417.6M | −€495.7M | −€467.4M | −€306.2M | €53.9M |
| Capital expenditure | €672.0K | €941.0K | €2.65M | €5.16M | €19.9M | €23.7M | €14.5M | €2.44M | — | — |
| Free cash flow | −€60.9M | −€96.0M | −€141.4M | −€181.1M | −€291.4M | −€441.4M | −€510.2M | −€469.8M | — | — |
| Share buybacks | — | — | — | — | — | €21.6M | €105.3M | €0 | €0 | €17.4M |
| Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | €95.9M | €36.0M | €57.8M | — | €101.0M | €158.0M | €213.6M | €247.5M |
| Growth (year over year) | +185.5% | −24.0% | +20.4% | — | +5.3% | +339.0% | +269.4% | — |
| Gross profit | €88.3M | €24.5M | €46.6M | — | €83.4M | €126.6M | €191.3M | €223.9M |
| Gross margin | 92.1% | 68.2% | 80.6% | — | 82.6% | 80.1% | 89.5% | 90.5% |
| Operating income | −€49.1M | −€133.3M | −€96.7M | — | −€104.2M | −€53.0M | €11.0M | €9.89M |
| Operating margin | −51.2% | −370.2% | −167.3% | — | −103.2% | −33.5% | 5.1% | 4.0% |
| Net income | −€131.0M | −€109.4M | −€99.2M | — | −€94.6M | −€38.9M | −€61.0M | −€33.6M |
| Net margin | −136.6% | −303.9% | −171.5% | — | −93.7% | −24.6% | −28.5% | −13.6% |
| EPS (diluted) | −€2.30 | −€1.91 | −€1.72 | — | −€1.58 | — | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | €320.2M | €258.7M | €625.5M | €559.5M | €517.9M | €494.0M | €539.1M | €616.0M |
| Total assets | €802.5M | €758.3M | €1.09B | €1.18B | €1.06B | €1.09B | €1.15B | €1.30B |
| Total liabilities | €1.04B | €1.08B | €1.19B | €1.29B | €1.25B | €1.28B | €1.33B | €1.47B |
| Shareholders' equity | −€238.2M | −€321.1M | −€97.3M | −€105.7M | −€189.8M | −€187.6M | −€174.1M | −€162.8M |
| Cash flow | ||||||||
| Operating cash flow | −€101.6M | −€61.3M | −€56.1M | — | −€14.3M | −€7.34M | €2.15M | €73.4M |
| Capital expenditure | €199.0K | €342.0K | €467.0K | — | — | — | — | — |
| Free cash flow | −€101.8M | −€61.6M | −€56.6M | — | — | — | — | — |
| Share buybacks | — | — | €0 | — | €17.4M | €0 | €0 | €0 |
From Ascendis Pharma A/S's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Euro (EUR), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Ascendis Pharma A/S in our feed yet.